AstraZeneca plc’s (AZN) Buy Rating Reiterated at Citigroup Inc.
Citigroup Inc. reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Thursday, MarketBeat.com reports. They currently have a GBX 6,000 ($78.35) target price on the biopharmaceutical company’s stock.
AZN has been the topic of a number of other research reports. Liberum Capital reissued a buy rating and issued a GBX 5,100 ($66.60) target price on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC reissued an overweight rating and issued a GBX 6,000 ($78.35) target price on shares of AstraZeneca plc in a report on Friday, April 28th. Deutsche Bank AG reissued a buy rating and issued a GBX 5,500 ($71.82) target price on shares of AstraZeneca plc in a report on Wednesday, March 15th. Societe Generale reissued a buy rating on shares of AstraZeneca plc in a report on Thursday, March 23rd. Finally, Credit Suisse Group reissued an underperform rating and issued a GBX 4,000 ($52.23) target price on shares of AstraZeneca plc in a report on Wednesday, April 19th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 5,251.80 ($68.58).
AstraZeneca plc (LON:AZN) opened at 5052.00 on Thursday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 63.96 billion. The company has a 50-day moving average price of GBX 5,259.89 and a 200 day moving average price of GBX 4,769.91.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.